Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed International Federation of Gynecology and Obstetrics (FIGO) stage (67) III or IV ovarian epithelial cancer or primary peritoneal cancer at presentation. Patients must have achieved a clinical complete response (disappearance of all clinical and radiological evidence of tumor) after only one regimen (4-6 cycles) of platinum and taxane-based standard chemotherapy received after tumor debulkment.
Normal serum CA125 (cancer-associated tumor marker) level within 7 days of first dose of sorafenib.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
All scans used to document complete response must be done within 30 days prior to randomization.
Patients must be able to swallow and retain oral medication.
You may not be if
Patients with any residual cancer tissue after the completion of chemotherapy detectable by standard Computed tomography (CT) or magnetic resonance imaging (MRI).
Prior local radiotherapy, neoadjuvant chemotherapy or intraperitoneal chemotherapy.
Histologic subtypes of ovarian cancer other than epithelial (i.e. sarcoma, lymphoma, germ cell).
Major surgery, open biopsy, or significant traumatic injury within 30 days prior to randomization.
Clareo Health | Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
